Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Florida Cancer Specialists & Research Institute Contributing to Global Advancements for Treatment of Gastrointestinal and Genitourinary Cancers | ||
By: PR Newswire Association LLC. - 30 Jan 2024 | Back to overview list |
|
FCS Experts Share Clinical Research and Case Presentations at Clinical Symposiums FORT MYERS, Fla., Jan. 30, 2024 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) continues to advance the treatment of gastrointestinal and genitourinary cancers, as evidenced by participation at two global gatherings held this month and sponsored by the American Society of Clinical Oncology (ASCO®). FCS medical oncologists and hematologists are co-authors of four FCS studies of advanced treatments featured at the ASCO® 2024 Gastrointestinal (GI) Cancers Symposium:
Elizabeth Guancial, MD, FCS medical oncologist and hematologist, served as a member of the program committee for the ASCO® 2024 Genitourinary (GU) Cancers Symposium, and participated as:
Also featured was a first in-human Phase 1 study of CC-94676, a first in-class androgen receptor ligand-directed degrader in patients with metastatic castration-resistant prostate cancer, co-authored by Manish Patel, MD. "The scientific research conducted daily in clinical trials across our statewide practice has an immediate and lasting impact on treatment decisions that are improving outcomes for cancer patients worldwide," said Bradley Monk, MD, who joined the practice earlier this year to serve as medical director of the FCS late-phase clinical research program. Manish Patel, MD, added, "Our studies and presentations demonstrate our focus and growing understanding of emerging and promising treatment modalities, including targeted immunotherapies and molecular-based treatments, which are improving survivorship for many forms of cancer once considered incurable. We are excited to share our findings and join with our colleagues to enhance and advance patient care." Dr. Patel oversees FCS' three early phase Drug Development Units in Sarasota, Lake Mary and Lake Nona. More than 300 active clinical trials are underway at FCS at any point in time. Gastrointestinal cancers affect the digestive tract organs, such as the stomach, large and small intestine, pancreas, colon, liver, rectum, anus and biliary system. Genitourinary cancers, including kidney and bladder cancers, occur in the urinary system of men and women and in the reproductive organs in men, such as prostate and testicular cancers. About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com) Celebrating its 40th year in 2024, FCS has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research, cutting-edge technologies and advanced treatments, including targeted therapies genomic-based treatment and immunotherapy. Our highest values are embodied by our outstanding team of highly trained and dedicated physicians, clinicians and staff. *Prior to approval View original content to download multimedia:https://www.prnewswire.com/news-releases/florida-cancer-specialists--research-institute-contributing-to-global-advancements-for-treatment-of-gastrointestinal-and-genitourinary-cancers-302048089.html SOURCE Florida Cancer Specialists & Research Institute |
||
|
||
Copyright 2024 PR Newswire Association LLC. | Back to overview list |